534 related articles for article (PubMed ID: 19438424)
1. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
[TBL] [Abstract][Full Text] [Related]
2. Low risk of Clostridium difficile infections in hospitalized patients with inflammatory bowel disease in a German tertiary referral center.
Ott C; Girlich C; Klebl F; Plentz A; Iesalnieks I; Schölmerich J; Obermeier F
Digestion; 2011; 84(3):187-92. PubMed ID: 21646782
[TBL] [Abstract][Full Text] [Related]
3. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
[TBL] [Abstract][Full Text] [Related]
4. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection.
Ben-Horin S; Margalit M; Bossuyt P; Maul J; Shapira Y; Bojic D; Chermesh I; Al-Rifai A; Schoepfer A; Bosani M; Allez M; Lakatos PL; Bossa F; Eser A; Stefanelli T; Carbonnel F; Katsanos K; Checchin D; Miera IS; Chowers Y; Moran GW;
Clin Gastroenterol Hepatol; 2009 Sep; 7(9):981-7. PubMed ID: 19523534
[TBL] [Abstract][Full Text] [Related]
5. Are patients with inflammatory bowel disease receiving optimal care?
Reddy SI; Friedman S; Telford JJ; Strate L; Ookubo R; Banks PA
Am J Gastroenterol; 2005 Jun; 100(6):1357-61. PubMed ID: 15929770
[TBL] [Abstract][Full Text] [Related]
6. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital.
Seiderer J; Göke B; Ochsenkühn T
Digestion; 2004; 70(1):3-9. PubMed ID: 15297773
[TBL] [Abstract][Full Text] [Related]
7. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients.
Nguyen GC; Kaplan GG; Harris ML; Brant SR
Am J Gastroenterol; 2008 Jun; 103(6):1443-50. PubMed ID: 18513271
[TBL] [Abstract][Full Text] [Related]
8. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Chen DM; Pritchard ML; Sandborn WJ
Clin Gastroenterol Hepatol; 2006 May; 4(5):621-30. PubMed ID: 16678077
[TBL] [Abstract][Full Text] [Related]
9. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
[TBL] [Abstract][Full Text] [Related]
10. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
11. Safety of infliximab in 10 years of clinical practice.
O'Donnell S; Murphy S; Anwar MM; O'Sullivan M; Breslin N; O'Connor HJ; Ryan BM; O'Morain CA
Eur J Gastroenterol Hepatol; 2011 Jul; 23(7):603-6. PubMed ID: 21602689
[TBL] [Abstract][Full Text] [Related]
12. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
14. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
[TBL] [Abstract][Full Text] [Related]
15. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study.
Singh H; Demers AA; Nugent Z; Mahmud SM; Kliewer EV; Bernstein CN
Gastroenterology; 2009 Feb; 136(2):451-8. PubMed ID: 18996382
[TBL] [Abstract][Full Text] [Related]
16. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.
Korelitz BI; Mirsky FJ; Fleisher MR; Warman JI; Wisch N; Gleim GW
Am J Gastroenterol; 1999 Nov; 94(11):3248-53. PubMed ID: 10566724
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
Lichtenstein GR; Olson A; Travers S; Diamond RH; Chen DM; Pritchard ML; Feagan BG; Cohen RD; Salzberg BA; Hanauer SB; Sandborn WJ
Am J Gastroenterol; 2006 May; 101(5):1030-8. PubMed ID: 16606351
[TBL] [Abstract][Full Text] [Related]
18. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
19. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study.
Chaparro M; Burgueño P; Iglesias E; Panés J; Muñoz F; Bastida G; Castro L; Jiménez C; Mendoza JL; Barreiro-de Acosta M; Senent SG; Gomollón F; Calvet X; García-Planella E; Gómez M; Hernández V; Hinojosa J; Mañosa M; Nyssen OP; Gisbert JP
Aliment Pharmacol Ther; 2012 Jan; 35(2):275-83. PubMed ID: 22142227
[TBL] [Abstract][Full Text] [Related]
20. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease.
Bousvaros A
Expert Rev Clin Immunol; 2010 Jul; 6(4):659-66. PubMed ID: 20594138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]